Tina W.’s Post

#ESMO23: #BMS presented efficacy results of the CheckMate-77T trial, demonstrating the efficacy of #Opdivo as neoadjuvant therapy in #NSCLC #patients https://lnkd.in/gpKjGB6X #pharma #pharmaceutical #Science #news #media #medicine #Europe #Cancer #Oncology #ESMO #ESMO2023

Zai Lab's partners Pfizer and Genmab jointly announced that the US FDA has approved their supplementary Biologics License Application (sBLA) for TIVDAK(®). This sets the stage for its use in the treatment of patients who are suffering from recurrent or metastatic cervical cancer, whose condition has progressed during or after chemotherapy. There's a considerable unmet need for cervical cancer treatment. The disease - recurrent and/or metastatic cervical cancer - is extremely destructive and often incurable; statistics show that up to 15% of adult cervical cancer patients experience metastasis at diagnosis, and for those diagnosed early and treated, as many as 61%(v) suffer recurrences. #QMportfolio #QMhealthcare #ZaiLab #Pfizer #Genmab #FDA #TIVDAKApproval #CervicalCancerTreatment

Introducing Pier Francesco, Director, Tumour Biotherapy Unit European Institute of Oncology, Italy, who will serve as the esteemed Chairperson for Day 2 at our MarketsandMarkets Next-Gen Immuno-Oncology Conference - EU Edition on 5th - 6th October 2023 at The Westin Grand Frankfurt, Germany. #oncology #oncologyresearch #cancer #medicine #oncologia #immunooncology #healthcare #therapy #pharmaceutical #conference #marketsandmarkets #NextGenIO #ConferenceRegistration #immunooncology

Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in the DESTINY-Breast06 Phase III trial. https://lnkd.in/d8a6-ras AstraZeneca Daiichi Sankyo US #breastcancer #oncology #oncologist #pharmacology #pharmaceuticals

The oncology drug market is projected to grow significantly, but there is still a tremendous unmet need among patients battling cancer. 🚀 #Oncology #CancerResearch #MedicalInnovation #Healthcare #OncologyDrugs #CancerTreatment #MedicalResearch #PatientCare #HealthInnovation #LifeSciences #ClinicalTrials #CancerAwareness #MedicalBreakthrough #CancerSupport #ResearchAndDevelopment #CancerProgress #OncologyResearch #HealthcareHeroes #CancerSurvivor #MedicalAdvances #Pharmaceuticals #HopeForCancer #CancerPrevention #HealthcareInnovation #FightingCancer #DrugDevelopment #MedicalField #CancerTherapies #BreakthroughsInMedicine #HealthcareCommunity

🌟!Exciting News in Prostate Cancer Treatment! 🌟 Telix Pharmaceuticals Limited announces positive rPFS data from the ProstACT SELECT trial of TLX591, an investigational radio-antibody-drug conjugate (rADC) therapy for mCRPC. The trial shows a median rPFS of 8.8 months, highlighting TLX591's efficacy and favorable safety profile. This advancement strengthens the role of radiopharmaceuticals in mCRPC, offering new hope for heavily pre-treated prostate cancer patients. Key Facts: 🩺 Median rPFS of 8.8 months 📈 Promising efficacy in advanced mCRPC 💊 Differentiated by a short two-week dosing regimen #Radiopharmaceuticals #ProstateCancer #MedicalInnovation #Oncology #Healthcare #radioisotopes

Passionate about Immuno-Oncology? We're seeking speakers for the 8th Annual Next-Gen Immuno-Oncology Conference, where we'll explore the latest advancements in London, UK on 07th-8th March 2024. If you're a leader in this field, we want to hear from you! Register as a Speaker now: https://lnkd.in/diNTkWYp #oncology #oncologyresearch #cancer #medicine #oncologia #immunooncology #healthcare #therapy #pharmaceutical #conference #marketsandmarkets  

Get ready for an enlightening session at the 8th Annual MarketsandMarkets Next-Gen Immuno Oncology Conference! Raj Mehta, CEO of Adendra Therapeutics, will be sharing his invaluable insights on recent advances and pressing challenges in Immuno-Oncology. Here's a sneak peek into what he'll be presenting. Mark your calendars for 07th - 8th March 2024 at Park Plaza Victoria London by Radisson. To learn more about the event, click here: https://lnkd.in/dvuWh2a6 #oncology #oncologyresearch #cancer #medicine #oncologia #immunooncology #healthcare #therapy #pharmaceutical #conference #marketsandmarkets  

Emerging Biopharma has become more increasingly invaluable to the development of cancer therapies over the last decade, up from 33% to 60% of trial starts over the span. Large pharma has conversely fell from 59% to just 28% over the decade. Interestingly, while large pharma oncology trials fell by 20% over the last 2 years, emerging biopharma trials remained stable - showing their resilience through economic turmoil. Read more about the state of oncology trials in IQVIA "Institute's Global Oncology Trends 2024" report: https://lnkd.in/eJsmZPSf #clinicaltrials #oncology

🌟 Thrilling News! 🌟 Signet Therapeutics Inc., a portfolio company of BOCG, has received FDA IND approval for its groundbreaking targeted therapy for diffuse gastric cancer, moving into Phase I clinical trials. This therapy is the world's first to integrate organoid disease models with AI, developed in collaboration with XtalPi, showcasing rapid and efficient drug development. Beyond gastric cancer, this therapy shows promise in treating ovarian, triple-negative breast, and pancreatic cancers. BOCG is proud to support Signet Therapeutics' mission to bring effective therapies to patients worldwide. Read more here: https://lnkd.in/gGqr2YuG #BOCGPortfolio #BOCGFamily #Biotech #FDAApproval #ClinicalTrials #TargetedTherapy #BOCG #SignetTherapeutics #AI #Organoids #CancerResearch #Investment